Header Logo

Connection

Shan Lu to Vaccines, DNA

Back to Details
This is a "connection" page, showing publications Shan Lu has written about Vaccines, DNA.
Shan Lu
Connection Strength
10.239
Vaccines, DNA
  1. Li H, Wang S, Hu G, Zhang L, Liu S, Lu S. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. Emerg Microbes Infect. 2021 Dec; 10(1):833-841.
    View in: PubMed
    Score: 0.720
  2. Flotte TR, Lu S. DNA Vaccination in 2018: An Update. Hum Gene Ther. 2018 09; 29(9):963-965.
    View in: PubMed
    Score: 0.575
  3. Wang S, Chou TH, Hackett A, Efros V, Wang Y, Han D, Wallace A, Chen Y, Hu G, Liu S, Clapham P, Arthos J, Montefiori D, Lu S. Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. Hum Vaccin Immunother. 2017 12 02; 13(12):2996-3009.
    View in: PubMed
    Score: 0.538
  4. Suschak JJ, Wang S, Fitzgerald KA, Lu S. A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. J Immunol. 2016 Jan 01; 196(1):310-6.
    View in: PubMed
    Score: 0.474
  5. Suschak JJ, Wang S, Fitzgerald KA, Lu S. Identification of Aim2 as a sensor for DNA vaccines. J Immunol. 2015 Jan 15; 194(2):630-6.
    View in: PubMed
    Score: 0.444
  6. Lu S. Novel vaccine technology and the future of vaccine science. Hum Vaccin Immunother. 2014; 10(5):1143-6.
    View in: PubMed
    Score: 0.416
  7. Wang S, Lu S. DNA immunization. Curr Protoc Microbiol. 2013 Nov 05; 31:18.3.1-18.3.24.
    View in: PubMed
    Score: 0.411
  8. Buglione-Corbett R, Pouliot K, Marty-Roix R, West K, Wang S, Lien E, Lu S. Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One. 2013; 8(9):e74820.
    View in: PubMed
    Score: 0.407
  9. Gil A, Shen S, Coley S, Gibson L, Diamond DJ, Wang S, Lu S. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. Hum Vaccin Immunother. 2013 Oct; 9(10):2120-32.
    View in: PubMed
    Score: 0.403
  10. Almansour I, Chen H, Wang S, Lu S. Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother. 2013 Oct; 9(10):2049-59.
    View in: PubMed
    Score: 0.403
  11. Lu S. Two is better than one. Lancet Infect Dis. 2011 Dec; 11(12):889-91.
    View in: PubMed
    Score: 0.356
  12. Wang S, Goguen JD, Li F, Lu S. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine. 2011 Sep 09; 29(39):6802-9.
    View in: PubMed
    Score: 0.338
  13. Wang S, Mboudjeka I, Goguen JD, Lu S. Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines. Vaccine. 2010 Feb 23; 28(8):2011-9.
    View in: PubMed
    Score: 0.318
  14. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010 Apr 09; 28(17):2999-3007.
    View in: PubMed
    Score: 0.318
  15. Lu S. Gene-based adjuvants: a new meaning. Hum Gene Ther. 2009 Oct; 20(10):1101-2.
    View in: PubMed
    Score: 0.310
  16. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008 Nov-Dec; 4(6):449-52.
    View in: PubMed
    Score: 0.292
  17. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol. 2008 Aug; 82(15):7369-78.
    View in: PubMed
    Score: 0.282
  18. Wang S, Parker C, Taaffe J, Sol?rzano A, Garc?a-Sastre A, Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008 Jul 04; 26(29-30):3626-33.
    View in: PubMed
    Score: 0.282
  19. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines. 2008 Mar; 7(2):175-91.
    View in: PubMed
    Score: 0.278
  20. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Feb 20; 26(8):1098-110.
    View in: PubMed
    Score: 0.275
  21. Shen S, Wang S, Britt WJ, Lu S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine. 2007 Apr 30; 25(17):3319-27.
    View in: PubMed
    Score: 0.257
  22. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol. 2006 Nov; 28(3):255-65.
    View in: PubMed
    Score: 0.251
  23. Wang S, Taaffe J, Parker C, Sol?rzano A, Cao H, Garc?a-Sastre A, Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol. 2006 Dec; 80(23):11628-37.
    View in: PubMed
    Score: 0.251
  24. Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology. 2006 Nov 25; 355(2):164-74.
    View in: PubMed
    Score: 0.250
  25. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006 May 22; 24(21):4531-40.
    View in: PubMed
    Score: 0.233
  26. Wang S, Chan KW, Wei D, Ma X, Liu S, Hu G, Park S, Pan R, Gu Y, Nazzari AF, Olia AS, Xu K, Lin BC, Louder MK, McKee K, Doria-Rose NA, Montefiori D, Seaman MS, Zhou T, Kwong PD, Arthos J, Kong XP, Lu S. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains. Nat Commun. 2024 May 21; 15(1):4301.
    View in: PubMed
    Score: 0.214
  27. Buglione-Corbett R, Pouliot K, Marty-Roix R, Li W, West K, Wang S, Morelli AB, Lien E, Lu S. Reduced MyD88 dependency of ISCOMATRIX? adjuvant in a DNA prime-protein boost HIV vaccine. Hum Vaccin Immunother. 2014; 10(4):1078-90.
    View in: PubMed
    Score: 0.105
  28. Wallace A, West K, Rothman AL, Ennis FA, Lu S, Wang S. Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). Hum Vaccin Immunother. 2013 Oct; 9(10):2095-102.
    View in: PubMed
    Score: 0.101
  29. Lu S, Grimes Serrano JM, Wang S. Polyvalent AIDS vaccines. Curr HIV Res. 2010 Dec; 8(8):622-9.
    View in: PubMed
    Score: 0.084
  30. Lu S, Wang S. Technical transformation of biodefense vaccines. Vaccine. 2009 Nov 05; 27 Suppl 4:D8-D15.
    View in: PubMed
    Score: 0.078
  31. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Jul 23; 26(31):3947-57.
    View in: PubMed
    Score: 0.071
  32. Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, Pal R, Wang S, Lu S, Markham P. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine. 2008 Aug 18; 26(35):4420-4.
    View in: PubMed
    Score: 0.071
  33. Wang S, Joshi S, Mboudjeka I, Liu F, Ling T, Goguen JD, Lu S. Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine. 2008 Mar 20; 26(13):1664-74.
    View in: PubMed
    Score: 0.069
  34. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology. 2008 Feb 05; 371(1):98-107.
    View in: PubMed
    Score: 0.068
  35. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005 Jun; 79(12):7933-7.
    View in: PubMed
    Score: 0.057
  36. Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005 Feb; 79(3):1906-10.
    View in: PubMed
    Score: 0.056
  37. Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, Chou TH, Goguen J, Lu S. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine. 2004 Sep 03; 22(25-26):3348-57.
    View in: PubMed
    Score: 0.054
  38. Liu F, Mboudjeka I, Shen S, Chou TH, Wang S, Ross TM, Lu S. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine. 2004 Apr 16; 22(13-14):1764-72.
    View in: PubMed
    Score: 0.053
  39. Costa MR, Pollara J, Edwards RW, Seaman MS, Gorny MK, Montefiori DC, Liao HX, Ferrari G, Lu S, Wang S. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. J Virol. 2016 Nov 15; 90(22):10362-10378.
    View in: PubMed
    Score: 0.032
  40. Pouliot K, Buglione-Corbett R, Marty-Roix R, Montminy-Paquette S, West K, Wang S, Lu S, Lien E. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine. 2014 Sep 03; 32(39):5049-56.
    View in: PubMed
    Score: 0.027
  41. Vaine M, Lu S, Wang S. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs. 2009; 23(3):137-53.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.